| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Stereotaxis, Inc.
13D/A
STXS · 85916J409
|
15.3% |
11/12/2026
Event 11/9/2026
|
||||
| DAFNA Capital Management, LLC | 15.1% | |||||
| Dr. Nathan Fischel | 15.3% | |||||
| Dr. Fariba Ghodsian | 15.1% | |||||
| DAFNA LifeScience, L.P. | 7.9% | |||||
| DAFNA LifeScience Select, L.P. | 7.3% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.